Skip to Main Content

Hello, everyone, and how are you today? A shiny sun and delightful breeze are enveloping the Pharmalot campus this morning, where the short person has left for gainful summer employment and the official mascot is happily snoozing in his corner. As for us, we are staring at the intimidating to-do list and quaffing cups of stimulation. Perhaps you can relate? In any event, we have once again assembled a few items of interest to get you started on your day. So here you go. Hope you conquer the world and keep us in mind when you run across something intriguing. …

Biogen (BIIB) mounted a vigorous defense of its controversial Alzheimer’s drug, Aduhelm, with the head of research and development releasing an open letter to the Alzheimer’s community that took direct aim at critics of approval, STAT writes. Al Sandrock, the R&D chief and an architect of many of Biogen’s successes, wrote that the purpose of the letter was to correct “misinformation and misunderstanding” about the drug and the approval process.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment